Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma
- 26 November 2007
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 53 (5), 917-930
- https://doi.org/10.1016/j.eururo.2007.11.037
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Renal Cell Carcinoma GuidelineEuropean Urology, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Understanding the Importance of Smart Drugs in Renal Cell CarcinomaEuropean Urology, 2006
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid TumorsClinical Cancer Research, 2005
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals Of Oncology, 2005
- Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursBritish Journal of Cancer, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- Validation of an index of the quality of review articlesJournal of Clinical Epidemiology, 1991